DDInter1018 DDInter927
Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic encephalopathy (PSE).[FDA Label,L6199,L6202] Despite being first synthesized in 1929, investigations regarding its possible use as a laxative for the treatment of chronic constipation did not occur until the 1960s and its first clinical use for treating PSE was not until 1966. Nevertheless, although lactulose received formal FDA approval in 1977 and has since become a readily available generic and brand-name non-prescription medication listed on the World Health Organization's List of Essential Medicines as one of the most effective and safe medicines employed in a health system, data regarding its optimal place in therapy is often ambiguous. Especially considering the use of lactulose as a laxative is typically only considered after lifestyle and dietary modifications fail and the
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Lactulose {u} (Compound) resembles {v} (Compound) Kanamycin
Lactulose {u} (Compound) resembles {v} (Compound) Acarbose
Lactulose {u} (Compound) is included by {v} (Pharmacologic Class) Acidifying Activity
Lactulose {u} (Compound) causes {v} (Side Effect) Abdominal discomfort
Lactulose {u} may cause a minor interaction that can limit clinical effects when taken with {v} Neomycin
Lactulose {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Perflutren
Lactulose {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ofloxacin
Lactulose (Compound) resembles Kanamycin (Compound)
Lactulose (Compound) resembles Acarbose (Compound)
Lactulose (Compound) is included by Acidifying Activity (Pharmacologic Class)
Lactulose (Compound) causes Abdominal discomfort (Side Effect)
Lactulose may cause a minor interaction that can limit clinical effects when taken with Neomycin
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Perflutren
Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Ofloxacin